Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2011-04-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study to Investigate Visual Performance of a Hydrophobic Monofocal IOL After Bilateral Implantation
NCT03423524
Visual Performance, Patient Satisfaction and PCO Rate After Implantation of a Trifocal Hydrophobic IOL
NCT03306342
The Incidence of Glistenings in the 2017 Intraocular Lenses Made by Alcon and Abbott Medical Optics
NCT03409185
Clinical Evaluation of a New Aspheric Intraocular Lens.
NCT00786565
Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens
NCT03633695
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Posterior Capsule Opacification (PCO) (pathological condition) - delayed clouding of the lens capsule after cataract surgery.
Glistenings - fluid-filled micro-vacuoles that form within the intraocular lens (IOL) optic when the IOL is in an aqueous environment. They may appear to be on the lens surface.
Artifacts - glares, halos, starbursts and/or shadows caused by IOLs.
Fibrosis - the formation of fibrous connective tissue, as in a scar.
Glare - undesirable sensation produced by brightness that is much greater than that to which the eyes are adapted. Causes annoyance, discomfort, or loss in visual performance.
Halos (symptom) - the appearance of hazy ring(s) around light.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who were implanted with EC-3 IOL
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aaren Scientific Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aaren Scientific Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
P. Dee G. Stephenson, M.D.
Role: PRINCIPAL_INVESTIGATOR
Stephenson Eye Associates
N. Timothy Peters, M.D.
Role: PRINCIPAL_INVESTIGATOR
Eyesight Ophthalmic Services PA
Christophe Pey, M.D.
Role: PRINCIPAL_INVESTIGATOR
Cabinet d'Ophtalmologie du Dr. Pey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stephenson Eye Associates
Venice, Florida, United States
Eyesight Ophthalmic Services
Dover, New Hampshire, United States
Cabinet d'Ophtalmologie du Dr. Pey
Le Puy-en-Velay, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DC-036 Addendum
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.